Mark Godsy, CEO and co-founder and Dr. Alan Shackelford, co-founder of Shackelford Pharmaceuticals, sat down to discuss using real-world data to guide cannabinoid-based drug development at the Benzinga Capital Cannabis Conference in Chicago.
Shackelford Pharma is a clinical-stage biopharmaceutical company developing medicines for neurological diseases with significant unmet patient needs. Its first drug candidate is targeted for use in the treatment of seizure disorders and is scheduled to enter a Phase 2 trial in Q2 2023.
Dr. Shackelford initially gained national attention for his breakthrough treatment of a young Dravet Syndrome patient with cannabinoids. The company has since leveraged real-world data from its clinical practice to guide its development decisions. The company’s research and development team has been involved in 43 FDA drug approvals, including six anti-epileptic drugs.
Watch Exclusive Footage Here
Interested in learning more about the Benzinga Cannabis Capital Conference? Get more information here.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.